The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema

Archives of Disease in Childhood

Volumn 88, Issue 11, 2003, Pages 981-984

  Clark, H ^a,b   Reid, K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; ANTIOXIDANT; COLLECTIN; RECOMBINANT PROTEIN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN D;

ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHMA; BACTERIAL INFECTION; CHRONIC LUNG DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYSTIC FIBROSIS; DRUG EFFECT; HUMAN; IMMUNOMODULATION; LUNG EMPHYSEMA; LUNG INFECTION; MYCOSIS; NEWBORN DISEASE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; VIRUS INFECTION;

CYSTIC FIBROSIS; HUMANS; INFANT, NEWBORN; LUNG DISEASES; PULMONARY EMPHYSEMA; PULMONARY SURFACTANT-ASSOCIATED PROTEIN D; PULMONARY SURFACTANTS; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 0345377580     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.88.11.981     Document Type: Review

References (53)

1. Nogee LM, Garnier G, Dietz HC, et al. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds. J Clin Invest 1994;93:1860-3.
2. Strong P, Kishore U, Morgan C, et al. A novel method of purifying lung surfactant proteins A and D from the lung lavage of alveolar proteinosis patients and from pooled amniotic fluid. J Immunol Methods 1998;220:139-49.
3. Clark HW, Reid KB, Sim RB. Collectins and innate immunity in the lung. Microbes Infect 2000;2:273-8.
4. LeVine AM, Whitsett JA. Pulmonary collectins and innate host defense of the lung. Microbes Infect 2001;3:161-6.
5. Botas C, Poulain F, Akiyama J, et al. Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D. Proc Natl Acad Sci U S A 1998;95:11869-74.
6. Wert SE, Yoshida M, LeVine AM, et al. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci USA 2000;97:5972-7.
7. Tino MJ, Wright JR. Surfactant proteins A and D specifically stimulate directed actin-based responses in alveolar macrophages. Am J Physiol 1999;276(1 Pt 1):L164-74.
8. Crouch EC, Persson A, Griffin GL, et al. Interactions of pulmonary surfactant protein D (SP-D) with human blood leukocytes. Am J Respir Cell Mol Biol 1995;12:410-15.
9. van Rozendaal BA, van de Lest CH, van Eijk M, et al. Aerosolized endotoxin is immediately bound by pulmonary surfactant protein D in vivo. Biochim Biophys Acta 1999;1454:261-9.
10. LeVine AM, Whitsett JA, Gwozdz JA, et al. Distinct effects of surfactant protein A or D deficiency during bacterial infection on the lung. J Immunol 2000;165:3934-40.
11. Fearon DT, Locksley RM. The instructive role of innate immunity in the acquired immune response. Science 1996;272:50-3.
12. Brinker KG, Martin E, Borron P, et al. Surfactant protein D enhances bacterial antigen presentation by bone marrow-derived dendritic cells. Am J Physiol Lung Cell Mol Physiol 2001;281:L1453-63.
13. Borron PJ, Crouch EC, Lewis JF, et al. Recombinant rat surfactant-associated protein D inhibits human T lymphocyte proliferation and IL-2 production. J Immunol 1998;161:4599-603.
14. Wang JY, Shieh CC, You PF, et al. Inhibitory effect of pulmonary surfactant proteins A and D on allergen-induced lymphocyte proliferation and histamine release in children with asthma. Am J Respir Crit Care Med 1998;158:510-18.
15. Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol 1997;61:375-80.
16. Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 2001;108:957-62.
17. Fadok VA, Bratton DL, Guthrie L, et al. Differential effects of apoptotic versus lysed cells on macrophage production of cytokines: role of proteases. J Immunol 2001;166:6847-54.
18. Clark H, Palaniyar N, Strong P, et al. Surfactant protein d reduces alveolar macrophage apoptosis in vivo. J Immunol 2002;169:2892-9.
19. Bridges JP, Davis HW, Damodarasamy M, et al. Pulmonary surfactant proteins A and D are potent endogenous inhibitors of lipid peroxidation and oxidative cellular injury. J Biol Chem 2000;275:38848-55.
20. Clark H, Reid KB. Structural requirements for surfactant protein D function in vitro and in vivo: therapeutic potential of recombinant SP-D. Immunobiology 2002;205:619-31.
21. Miyamura K, Malhotra R, Hoppe HJ, et al. Surfactant proteins A (SP-A) and D (SP-D): levels in human amniotic fluid and localization in the fetal membranes. Biochim Biophys Acta 1994;1210:303-7.
22. Mariencheck W, Crouch E. Modulation of surfactant protein D expression by glucocorticoids in fetal rat lung. Am J Respir Cell Mol Biol 1994;10:419-29.
23. Wang JY, Yeh TF, Lin YC, et al. Measurement of pulmonary status and surfactant protein levels during dexamethasone treatment of neonatal respiratory distress syndrome. Thorax 1996;51:907-13.
24. Beresford M, Shaw N. The role of pulmonary surfactant proteins A, B and D in preterm infants ventilated for respiratory distress receiving different surfactant therapies. Early Human Development 2001;66:41-62.
25. Li YH, Tullus K. Microbial infection and inflammation in the development of chronic lung disease of prematurity. Microbes Infect 2002;4:723-32.
26. Rauprich P, Moller O, Walter G, et al. Influence of modified natural or synthetic surfactant preparations on growth of bacteria causing infections in the neonatal period. Clin Diagn Lab Immunol 2000;7:817-22.
27. Robertson B. The evolution of neonatal respiratory distress syndrome into chronic lung disease. Eur Respir J Suppl 1989;3:33s-37s.
28. Speer CP. Inflammatory mechanisms in neonatal chronic lung disease. Eur J Pediatr 1999;158(suppl 1 ):S18-22.
29. Grigg JM, Savill JS, Sarraf C, et al. Neutrophil apoptosis and clearance from neonatal lungs. Lancet 1991;338:720-2.
30. Hargitai B, Szabo V, Hajdu J, et al. Apoptosis in various organs of preterm infants: histopathologic study of lung, kidney, liver, and brain of ventilated infants. Pediatr Res 2001;50:110-14.
31. Clement A, Chadelat K, Sardet A, et al. Alveolar macrophage status in bronchopulmonary dysplasia. Pediatr Res 1988;23:470-3.
32. Merritt TA, Stuard ID, Puccia J. Newborn tracheal aspirate cytology: classification during respiratory distress syndrome and bronchopulmonary dysplasia. J Paediatr 1981;98:949-56.
33. Arnon S, Grigg J, Silverman M. Pulmonary inflammatory cells in ventilated preterm infants: effect of surfactant treatment. Arch Dis Child 1993;69(1 spec no.):44-8.
34. Bals R, Weiner DJ, Wilson JM. The innate immune system in cystic fibrosis lung disease. J Clin Invest 1999;103:303-7.
35. Tino MJ, Wright JR. Surfactant protein A stimulates phagocytosis of specific pulmonary pathogens by alveolar macrophages. Am J Physiol 1996;270(4 pt 1):L677-88.
36. Madan T, Eggleton P, Kishore U, et al. Binding of pulmonary surfactant proteins A and D to Aspergillus fumigatus conidia enhances phagocytosis and killing by human neutrophils and alveolar macrophages. Infect Immun 1997;65:3171-9.
37. Postle AD, Mander A, Reid KB, et al. Deficient hydrophilic lung surfactant proteins A and D with normal surfactant phospholipid molecular species in cystic fibrosis. Am J Respir Cell Mol Biol 1999;20:90-8.
38. von Bredow C, Birrer P, Griese M. Surfactant protein A and other bronchoalveolar lavage fluid proteins are altered in cystic fibrosis. Eur Respir J 2001;17:716-22.
39. Madan T, Kishore U, Singh M, et al. Surfactant proteins A and D protect mice against pulmonary hypersensitivity induced by Aspergillus fumigatus antigens and allergens. J Clin Invest 2001;107:467-75.
40. Strong P, Reid KB, Clark H. Intranasal delivery of a truncated recombinant human SP-D is effective at down regulating allergic hypersensitivity in mice sensitised to allergens of Aspergillus fumigatus. Clin Exp Immunol 2002;130:19-24.
41. Vandivier RW, Fadok VA, Ogden CA, et al. Impaired clearance of apoptotic cells from cystic fibrosis airways. Chest 2002;121(3 suppl):89S.
42. Sandford AJ, Joos L, Pare PD. Genetic risk factors for chronic obstructive pulmonary disease. Curr Opin Pulm Med 2002;8:87-94.
43. Aoshiba K, Tamaoki J, Nagai A. Acute cigarette smoke exposure induces apoptosis of alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2001;281:L1392-401.
44. D'Agostini F, Balansky RM, Izzotti A, et al. Modulation of apoptosis by cigarette smoke and cancer chemopreventive agents in the respiratory tract of rats. Carcinogenesis 2001;22:375-80.
45. Majo J, Ghezzo H, Cosio MG. Lymphocyte population and apoptosis in the lungs of smokers and their relation to emphysema. Eur Respir J 2001;17:946-53.
46. Honda Y, Takahashi H, Kuroki Y, et al. Decreased contents of surfactant proteins A and D in BAL fluids of healthy smokers. Chest 1996;109:1006-9.
47. Guo X, Lin HM, Lin Z, et al. Surfactant protein gene A, B, and D marker alleles in chronic obstructive pulmonary disease of a Mexican population. Eur Respir J 2001;18:482-90.
48. Greene KE, King TE Jr, Kuroki Y, et al. Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis. Eur Respir J 2002;19:439-46.
49. Kuan SF, Rust K, Crouch E. Interactions of surfactant protein D with bacterial lipopolysaccharides. Surfactant protein D is an Escherichia coli-binding protein in bronchoalveolar lavage. J Clin Invest 1992;90:97-106.
50. Ofek I, Mesika A, Kalina M, et al. Surfactant protein D enhances phagocytosis and killing of unencapsulated phase variants of Klebsiella pneumoniae. Infect Immun 2001;69:24-33.
51. Hickling TP, Bright H, Wing K, et al. A recombinant trimeric surfactant protein D carbohydrate recognition domain inhibits respiratory syncytial virus infection in vitro and in vivo. Eur J Immunol 1999;29:3478-84.
52. O'Riordan DM, Standing JE, Kwon KY, et al. Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 1995;95:2699-710.
53. Schelenz S, Malhotra R, Sim RB, et al. Binding of host collectins to the pathogenic yeast Cryptococcus neoformans: human surfactant protein D acts as an agglutinin for acapsular yeast cells. Infect Immun 1995;63:3360-6.